RSLS - רווח נקי למניה (EPS TTM) ReShape Lifesciences Inc

In the medtech sector, ReShape Lifesciences (RSLS) is fighting for survival under a regime of strict resource austerity. The company is implementing eco-friendly ESG production standards and ensuring the careful delivery of high-precision systems to clinics. The EPS trend over the last 12 months on the GURU.Markets chart demonstrates current dynamics, where -486.68 forms the current metric value, reflecting the real momentum of shareholder equity.

Net income per share (TTM) measures the portion of equity attributable to a single share over a trailing twelve-month period. For ReShape Lifesciences (RSLS), this metric reflects the efficiency of cost management in the production of medical devices. By analyzing the trailing twelve-month EPS chart, an investor can see the impact of supply chain diversification on bottom-line profitability. This indicator demonstrates the business's actual ability to generate income, serving as a key basis for assessing the asset's fair value.